Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019

被引:2
作者
Lob, Sibylle H. [1 ]
DePestel, Daryl D. [2 ]
DeRyke, C. Andrew [2 ]
Kazmierczak, Krystyna M. [1 ]
Young, Katherine [2 ]
Motyl, Mary R. [2 ]
Sahm, Daniel F. [1 ]
机构
[1] IHMA, 2122 Palmer Dr, Schaumburg, IL 60173 USA
[2] Merck & Co Inc, Kenilworth, NJ USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2021年 / 8卷 / 07期
关键词
ceftolozane/tazobactam; ICU; imipenem/relebactam; Pseudomonas aeruginosa; respiratory tract infection; GRAM-NEGATIVE BACTERIA; BLOOD-STREAM; RESISTANCE; PNEUMONIA; MUTATIONS; IMPACT;
D O I
10.1093/ofid/ofab320
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Carbapenem-nonsusceptible and multidrug-resistant (MDR) P. aeruginosa, which are more common in patients with lower respiratory tract infections (LRTIs) and in patients in intensive care units (ICUs), pose difficult treatment challenges and may require new therapeutic options. Two beta-lactam/beta-lactamase inhibitor combinations, ceftolozane/tazobactam (C/T) and imipenem/relebactam (IMI/REL), are approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. Methods. The Clinical and Laboratory Standards Institute-defined broth microdilution methodology was used to determine minimum inhibitory concentrations (MICs) against P. aeruginosa isolates collected from patients with LRTIs in ICUs (n = 720) and non-ICU wards (n = 914) at 26 US hospitals in 2017-2019 as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program. Results. Susceptibility to commonly used beta-lactams including carbapenems was 5-9 percentage points lower and MDR rates 7 percentage points higher among isolates from patients in ICUs than those in non-ICU wards (P<.05). C/T and IMI/REL maintained activity against 94.0% and 90.8% of ICU isolates, respectively, while susceptibility to all comparators except amikacin (96.0%) was 63%-76%. C/T and IMI/REL inhibited 83.1% and 68.1% of meropenem-nonsusceptible (n = 207) and 71.4% and 65.7% of MDR ICU isolates (n = 140), respectively. Among all ICU isolates, only 2.5% were nonsusceptible to both C/T and IMI/REL, while 6.7% were susceptible to C/T but not to IMI/REL and 3.5% were susceptible to IMI/REL but not to C/T. Conclusions. These data suggest that susceptibility to both C/T and IMI/REL should be considered for testing at hospitals, as both agents could provide important new options for treating patients with LRTIs, especially in ICUs where collected isolates show substantially reduced susceptibility to commonly used beta-lactams.
引用
收藏
页数:7
相关论文
共 36 条
  • [21] Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections:: Impact of delayed appropriate antibiotic selection
    Lodise, Thomas P., Jr.
    Patel, Nimish
    Kwa, Andrea
    Graves, Jeffrey
    Furuno, Jon P.
    Graffunder, Eileen
    Lomaestro, Ben
    McGregor, Jessina C.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (10) : 3510 - 3515
  • [22] Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study
    McCann, Eilish
    Srinivasan, Arjun
    DeRyke, C. Andrew
    Ye, Gang
    DePestel, Daryl D.
    Murray, John
    Gupta, Vikas
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (10):
  • [23] Pseudomonas aeruginosa bloodstream infection:: Importance of appropriate initial antimicrobial treatment
    Micek, ST
    Lloyd, AE
    Ritchie, DJ
    Reichley, RM
    Fraser, VJ
    Kollef, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) : 1306 - 1311
  • [24] Moise PA, JAC ANTIMICROBIAL RE
  • [25] Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases
    Mushtaq, Shazad
    Meunier, Daniele
    Vickers, Anna
    Woodford, Neil
    Livermore, David M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (02) : 434 - 442
  • [26] Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections
    Parsels, Katie A.
    Mastro, Keri A.
    Steele, Jeffrey M.
    Thomas, Stephen J.
    Kufel, Wesley D.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (06) : 1379 - 1391
  • [27] Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17)
    Sader, Helio S.
    Castanheira, Mariana
    Mendes, Rodrigo E.
    Flamm, Robert K.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (11) : 3053 - 3059
  • [28] Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016
    Sader, Helio S.
    Castanheira, Mariana
    Duncan, Leonard R.
    Flamm, Robert K.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 92 (01) : 69 - 74
  • [29] Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia
    Sader, Helio S.
    Castanheira, Mariana
    Flamm, Robert K.
    Mendes, Rodrigo E.
    Farrell, David J.
    Jones, Ronald N.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 46 (01) : 53 - 59
  • [30] Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)
    Sader, Helio S.
    Farrell, David J.
    Flamm, Robert K.
    Jones, Ronald N.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2014, 78 (04) : 443 - 448